Journal article
P14.41 Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC-26101 trial
- Furtner, J Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
- Genbrugge, E European Organization for Research and Treatment of Cancer, Brussels, Belgium
- Gorlia, T European Organization for Research and Treatment of Cancer, Brussels, Belgium
- Bendszus, M University Medical Center and German Cancer Research Center, Heidelberg, Germany
- Nowosielski, M Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
- Golfinopoulos, V European Organization for Research and Treatment of Cancer, Brussels, Belgium
- Weller, M University Hospital and University of Zurich, Zurich, Switzerland
- van den Bent, M J Department of Neurology/Neuro-Oncology, Erasmus MC - Cancer Institute, Rotterdam, Netherlands
- Wick, W Neurology Clinic, University of Heidelberg, Clinical Cooperation Unit (CCU) Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Preusser, M Department of Medicine I, Medical University of Vienna, Vienna, Austria
- 2019-9-6
Published in:
- Neuro-Oncology. - Oxford University Press (OUP). - 2019, vol. 21, no. Supplement_3, p. iii76-iii76
English
Abstract
BACKGROUND
Temporal muscle thickness (TMT) was described as surrogate marker of skeletal muscle mass and prognostic parameter in brain metastasis patients. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma.
MATERIAL AND METHODS
TMT was analyzed on the baseline cranial magnetic resonance (MR) images of 596 patients with progression of glioblastoma after radio-chemotherapy enrolled in the EORTC 26101 trial. An optimal TMT cutoff for overall survival (OS) and progression free survival (PFS) was defined in the training cohort (n=260 patients enrolled in phase 2 part of EORTC 26101). Patients were grouped as “below” or “above” the TMT cutoff and associations with OS and PFS were tested using the Cox model. The findings were validated in a test cohort (n=308 patients enrolled in phase 3 part of EORTC 26101).
RESULTS
An optimal baseline TMT cutoff of 7.2 mm was obtained in the training cohort for both OS and PFS (AUC=0.64). Univariate analyses estimated a hazard ratio (HR) of 0.54 (95% CI:0.42, 0.70, p<0.0001) for OS and a HR of 0.49 (95% CI: 0.38, 0.64, p<0.0001) for PFS for the comparison of training cohort patients above versus below the TMT cutoff. This was confirmed in multivariate testing for OS (HR of 0.54, 95% CI: 0.41, 0.70, p<0.0001) and PFS (HR of 0.47, 95% CI: 0.36, 0.61, p<0.0001) adjusted for the important risk factors with relevance in the trial for OS (Steroid use at baseline, HR of 1.58, 95% CI: 1.19, 2.11, p = 0.002; MGMT Status, HR of 0.51, 95% CI: 0.36, 0.72, p<0.001; maximum diameter ≥ 40mm, HR of 2.49, 95% CI: 1.41, 4.41, p = 0.002; central hemisphere involvement, HR of 1.97, 95% CI: 1.37, 2.84, p<0.001) and PFS (Neurological deficit, HR of 1.44, 95% CI:1.09, 1,92, p = 0.011; Steroid use at baseline, HR of 1.42, 95% CI: 1.08, 1.86, p = 0.011; MGMT status, HR of 0.61, 95% CI: 0.43, 0.87, p = 0.007; Number of target lesion >1, HR of 2.47, 95% CI: 1.38, 4,41, p = 0.002). Similar results were obtained in the validation cohort.
CONCLUSION
TMT is an independent prognostic parameter in patients with progressive glioblastoma. This parameter is easily assessable on routine MR images and may help to better define frail patient populations and thus facilitate patient management by supporting patient stratification for therapeutic interventions or clinical trials.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1093/neuonc/noz126.276
- ISSN 1522-8517
- Persistent URL
- https://sonar.ch/global/documents/31084
Statistics
Document views: 32
File downloads: